Literature DB >> 17975668

OX40 ligand expressed by DCs costimulates NKT and CD4+ Th cell antitumor immunity in mice.

Jamal Zaini1, Sita Andarini, Minoru Tahara, Yasuo Saijo, Naoto Ishii, Kazuyoshi Kawakami, Masaru Taniguchi, Kazuo Sugamura, Toshihiro Nukiwa, Toshiaki Kikuchi.   

Abstract

The exceptional immunostimulatory capacity of DCs makes them potential targets for investigation of cancer immunotherapeutics. We show here in mice that TNF-alpha-stimulated DC maturation was accompanied by increased expression of OX40 ligand (OX40L), the lack of which resulted in an inability of mature DCs to generate cellular antitumor immunity. Furthermore, intratumoral administration of DCs modified to express OX40L suppressed tumor growth through the generation of tumor-specific cytolytic T cell responses, which were mediated by CD4+ T cells and NKT cells. In the tumors treated with OX40L-expressing DCs, the NKT cell population significantly increased and exhibited a substantial level of IFN-gamma production essential for antitumor immunity. Additional studies evaluating NKT cell activation status, in terms of IFN-gamma production and CD69 expression, indicated that NKT cell activation by DCs presenting alpha-galactosylceramide in the context of CD1d was potentiated by OX40 expression on NKT cells. These results show a critical role for OX40L on DCs, via binding to OX40 on NKT cells and CD4+ T cells, in the induction of antitumor immunity in tumor-bearing mice.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17975668      PMCID: PMC2045612          DOI: 10.1172/JCI32693

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  64 in total

1.  Robust B cell immunity but impaired T cell proliferation in the absence of CD134 (OX40).

Authors:  S D Pippig; C Peña-Rossi; J Long; W R Godfrey; D J Fowell; S L Reiner; M L Birkeland; R M Locksley; A N Barclay; N Killeen
Journal:  J Immunol       Date:  1999-12-15       Impact factor: 5.422

Review 2.  Immunobiology of dendritic cells.

Authors:  J Banchereau; F Briere; C Caux; J Davoust; S Lebecque; Y J Liu; B Pulendran; K Palucka
Journal:  Annu Rev Immunol       Date:  2000       Impact factor: 28.527

3.  OX40-deficient mice are defective in Th cell proliferation but are competent in generating B cell and CTL Responses after virus infection.

Authors:  M Kopf; C Ruedl; N Schmitz; A Gallimore; K Lefrang; B Ecabert; B Odermatt; M F Bachmann
Journal:  Immunity       Date:  1999-12       Impact factor: 31.745

4.  Ox40-ligand has a critical costimulatory role in dendritic cell:T cell interactions.

Authors:  A I Chen; A J McAdam; J E Buhlmann; S Scott; M L Lupher; E A Greenfield; P R Baum; W C Fanslow; D M Calderhead; G J Freeman; A H Sharpe
Journal:  Immunity       Date:  1999-12       Impact factor: 31.745

5.  Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo.

Authors:  N C Fernandez; A Lozier; C Flament; P Ricciardi-Castagnoli; D Bellet; M Suter; M Perricaudet; T Tursz; E Maraskovsky; L Zitvogel
Journal:  Nat Med       Date:  1999-04       Impact factor: 53.440

6.  Dendritic cells modified to express CD40 ligand elicit therapeutic immunity against preexisting murine tumors.

Authors:  T Kikuchi; M A Moore; R G Crystal
Journal:  Blood       Date:  2000-07-01       Impact factor: 22.113

7.  In vivo identification of glycolipid antigen-specific T cells using fluorescent CD1d tetramers.

Authors:  K Benlagha; A Weiss; A Beavis; L Teyton; A Bendelac
Journal:  J Exp Med       Date:  2000-06-05       Impact factor: 14.307

8.  Sustained expansion of NKT cells and antigen-specific T cells after injection of alpha-galactosyl-ceramide loaded mature dendritic cells in cancer patients.

Authors:  David H Chang; Keren Osman; John Connolly; Anjli Kukreja; Joseph Krasovsky; Maggi Pack; Aisha Hutchinson; Matthew Geller; Nancy Liu; Rebecca Annable; Jennifer Shay; Kelly Kirchhoff; Nobusuke Nishi; Yoshitaka Ando; Kunihiko Hayashi; Hani Hassoun; Ralph M Steinman; Madhav V Dhodapkar
Journal:  J Exp Med       Date:  2005-05-02       Impact factor: 14.307

9.  Tracking the response of natural killer T cells to a glycolipid antigen using CD1d tetramers.

Authors:  J L Matsuda; O V Naidenko; L Gapin; T Nakayama; M Taniguchi; C R Wang; Y Koezuka; M Kronenberg
Journal:  J Exp Med       Date:  2000-09-04       Impact factor: 14.307

10.  Impairment of antigen-presenting cell function in mice lacking expression of OX40 ligand.

Authors:  K Murata; N Ishii; H Takano; S Miura; L C Ndhlovu; M Nose; T Noda; K Sugamura
Journal:  J Exp Med       Date:  2000-01-17       Impact factor: 14.307

View more
  50 in total

Review 1.  Signaling through OX40 enhances antitumor immunity.

Authors:  Shawn M Jensen; Levi D Maston; Michael J Gough; Carl E Ruby; William L Redmond; Marka Crittenden; Yuhuan Li; Sachin Puri; Christian H Poehlein; Nick Morris; Magdalena Kovacsovics-Bankowski; Tarsem Moudgil; Chris Twitty; Edwin B Walker; Hong-Ming Hu; Walter J Urba; Andrew D Weinberg; Brendan Curti; Bernard A Fox
Journal:  Semin Oncol       Date:  2010-10       Impact factor: 4.929

2.  Engagement of glycosylphosphatidylinositol-anchored proteins results in enhanced mouse and human invariant natural killer T cell responses.

Authors:  Lisa A Mannik; Ian Chin-Yee; Shayan Sharif; Luc Van Kaer; Terry L Delovitch; S M Mansour Haeryfar
Journal:  Immunology       Date:  2010-11-11       Impact factor: 7.397

Review 3.  Immunotherapeutic strategies targeting natural killer T cell responses in cancer.

Authors:  Susannah C Shissler; Dominique R Bollino; Irina V Tiper; Joshua P Bates; Roshanak Derakhshandeh; Tonya J Webb
Journal:  Immunogenetics       Date:  2016-07-08       Impact factor: 2.846

Review 4.  Whole cell vaccines--past progress and future strategies.

Authors:  Bridget P Keenan; Elizabeth M Jaffee
Journal:  Semin Oncol       Date:  2012-06       Impact factor: 4.929

Review 5.  Anti-tumor potential of type-I NKT cells against CD1d-positive and CD1d-negative tumors in humans.

Authors:  Leonid S Metelitsa
Journal:  Clin Immunol       Date:  2010-11-20       Impact factor: 3.969

Review 6.  Harnessing invariant NKT cells in vaccination strategies.

Authors:  Vincenzo Cerundolo; Jonathan D Silk; S Hajar Masri; Mariolina Salio
Journal:  Nat Rev Immunol       Date:  2009-01       Impact factor: 53.106

Review 7.  Immunomodulation in the treatment of haematological malignancies.

Authors:  Michela Cesco-Gaspere; Emma Morris; Hans J Stauss
Journal:  Clin Exp Med       Date:  2009-02-24       Impact factor: 3.984

8.  The upregulated expression of OX40/OX40L and their promotion of T cells proliferation in the murine model of asthma.

Authors:  Wei Lei; Da-Xiong Zeng; Can-Hong Zhu; Gao-Qin Liu; Xiu-Qin Zhang; Chang-Guo Wang; Qin Wang; Jian-An Huang
Journal:  J Thorac Dis       Date:  2014-07       Impact factor: 2.895

9.  TNF superfamily receptor OX40 triggers invariant NKT cell pyroptosis and liver injury.

Authors:  Peixiang Lan; Yihui Fan; Yue Zhao; Xiaohua Lou; Howard P Monsour; Xiaolong Zhang; Yongwon Choi; Yaling Dou; Naoto Ishii; Rafik M Ghobrial; Xiang Xiao; Xian Chang Li
Journal:  J Clin Invest       Date:  2017-04-24       Impact factor: 14.808

Review 10.  The role of costimulatory molecules in allergic disease and asthma.

Authors:  Vincent Lombardi; Abinav K Singh; Omid Akbari
Journal:  Int Arch Allergy Immunol       Date:  2009-09-29       Impact factor: 2.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.